explore -WSS

explore

author：focus 2025-08-28 13:02:14 - browse：26

The Johnson and Johnson booth at ESMO in Madrid. — The Johnson & Johnson booth at ESMO 2023. Andrew Joseph/STAT

MADRID — A competition has been brewing between two pharma titans — Johnson & Johnson and AstraZeneca — to gain an edge in the market for targeted lung cancer treatments. A primetime presentation here Monday amounted to the latest salvo.

At the annual meeting of the European Society for Medical Oncology, J&J unveiled three studies of its drug Rybrevant in different patient groups with non-small cell lung cancer with EGFR mutations. All were successful, with the drug, sometimes used in combination with other therapies, helping stave off progression of the disease.

In an interview, Mark Wildgust, J&J’s vice president of global medical affairs for oncology, framed the totality of the research as a case that Rybrevant could become a regularly used treatment for these patients.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Lawsuit alleges UnitedHealth Group unit illegally denied claims

explore

WSS

Scientists inch closer to single

Readout Newsletter: Allogene's pivot, Illumina exec to lead Delfi

Mitch McConnell episode has important public health takeaway

UCB departs biotech trade group BIO

Listen: Biogen's situation, Wegovy's risks, & biotech insider trading

No plane should take off without an EpiPen onboard

explore

explore

entertainment

New air purifier tech could be key to improving indoor air quality

Scientists inch closer to single

Peter Hotez and the public health issue of online harassment

Vertex non

Drug repurposing or repositioning? The language matters

Burning questions for the 2024 JPM Healthcare Conference

The cancer drug shortage isn’t new — and neither are the solutions

No plane should take off without an EpiPen onboard

In Memoriam: Notable people who died in 2023

White House finalizes ITC's import ban of latest Apple Watches

hotspot

Readout Newsletter: Allogene's pivot, Illumina exec to lead Delfi

Wildfire pollution widens asthma inequities on Long Island

No plane should take off without an EpiPen onboard

JPM 2024 Day 3: Biotech Updates from Verve, Roivant, etc

Goldman Sachs launches $650M fund for life science investments

Insitro, AI biotech unicorn, brings cash, new research to JPM 2024

explore

explore

explore

leisure time